Antibody immunosuppressive therapy in solid-organ transplant: Part I

mAbs

Volumn 2, Issue 2, 2010, Pages 148-156

  Mahmud, Nadim ^a   Klipa, Dusko ^b   Ahsan, Nasimul ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Complications; Heart; Induction; Kidney; Liver; Lung; Monoclonal; Polyclonal; Rejection; Transplants

Indexed keywords

ALEMTUZUMAB; ANTIBODY; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; MONOCLONAL ANTIBODY; PLACEBO; POLYCLONAL ANTIBODY; TACROLIMUS;

FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; ORGAN TRANSPLANTATION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MONITORING, PHYSIOLOGIC; NEOPLASMS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION;

EID: 77953654209     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.2.11159     Document Type: Review

References (126)

1. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. New Engl J Med 1963; 268:1315-23.
2. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 1979; 8151:1033-6.
3. Norman D, Turka L. Primer on Transplantation. Wiley Blackwell 2001.
4. Collins WA, Humphreys RM, Davis MB, Ibele WE, Dworkin M, Kinsey J, et al. The Crime of Saving Lives: The FDA, John Najarian and Minnesota ALG. Arch Surg 1996; 131:451-2.
5. Wechter WJ, Brodie JA, Morrell RM, Rafi M, Schultz JR. Antithymocyte Globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation 1979; 28:294-302.
6. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppresion therapy in adult renal transplant recipients. Transplantation 1999; 67:1011-8.
7. Scientific Registry of Transplant Recipients. Data tables: Kidney Tables. Accessed October 15th from www.unos.org.
8. Meier-Kriesche HU, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB, et al. Increased Impact of Acute Rejection On Chronic Allograft Failure in Recent Era. Transplantation 2005; 70:1098-100.
9. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation 2006; 81:953-65.
10. Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004; 10:404-7.
11. Moreno JM, Cuervas-Mons V, Rubio E, Pons F, Herreros de TA, Turrion VS, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors and impact on mortality. Transpl Proc 2003; 35:1907-8.
12. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation using calcineurin-based immunotherapy. Transplantation 2001; 72:1934-9.
13. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl 2008; 14:66-72.
14. Higgins R, Kirklin JK, Brown RN, Rayburn BK, Wagoner L, Oren R, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Transplant 2005; 24:392-400.
15. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation; results of a randomized, prospective study. Chest 1999; 116:127-33.
16. Hachem RR, Edwards LB, Yusen RD, Chakinala MM, Alexander Patterson G, Trulock EP. The impact on survival after lung transplantation: an analysis of international society for the heart and lung transplantation registry. Clin Transplant 2008; 22:603-8.
17. RATG [package insert]. New York, NY: Pfizer Corp 2005.
18. RATG [package insert]. Cambridge, MA: Genzyme Corp 2009.
19. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772-86.
20. Ahsan N, Shah KV. In: Nasimul Ahsan. Ed. Polyomaviruses and human diseases, New York: Springer Science 2006; 1-18.
21. Crippin JS. Late allograft failure: liver. In: Nasimul Ahsan. Ed. Chronic allograft failure: natural history, pathogenesis. Diagnosis and management, Austin, TX: Landes Bioscience 2008; 159-63.
22. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de novo malignancies in renal allograft patients. Eur J Surg Oncol 2001; 27:409-13.
23. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression the risk of post transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4:87-93.
24. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32:535-9.
25. Thistlethwaite JR Jr, Cosimi AB, Delmonico FL, Rubin RH, Talkoff-Rubin N, Nelson PW, et al. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 1984; 38:695-701.
26. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985; 313:337-42.
27. Chatenoud L, Bach JF. T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release. C R Seances Soc Biol Fil 1991; 185:268-77.
28. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauq L, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47:606-8.
29. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present and future. Semin Nephrol 2000; 20:108-25.
30. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51:865-94.
31. Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose RATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 1998; 11:231-6.
32. Heifets M, Saeed MI, Parikh MH, Sierka D, Kumar MS. Induction immunosuppression in kidney transplant recipients older than 60 years of age: safety and efficacy of RATG, OKT3 and Simulect. Drugs & Aging 2004; 21:747-56.
33. Kainz A, Korbely R, Soleiman A, Mayer B, Oberbauer R. Antithymocyte globulin use for treatment of biopsy confirmed acute rejection is associated with prolonged renal allograft survival. Transpl Int 2009; http://www.ncbi.nlm. nih.gov/pubmed/19719467.
34. Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, et al. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol. J Cardiovasc Surg 1993; 34:135-40.
35. Zhang R, Haverich A, Struber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant 2008; 27:603-9.
36. Colonna JO, Goldstein LI, Brems JJ, Vargas JH, Brill JE, Berquist WJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 1987; 122:1120-3.
37. Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993; 55:87-91.
38. Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, et al. Long term management of liver transplant rejection in children. BioDrugs 2000; 14:31-48.
39. Rosen HR, Shackleton CR, Higa L, Grainek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:1453-7.
40. Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl 2006; 12:38-47.
41. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8:19-27.
42. Barlow CW, Moon MR, Green GR, Gamberg P, Theodore J, Reitz BA, et al. Rabbit antithymocyte globulin versus OKT3 induction therapy after heartlung and lung transplantation: effect on survival, rejection, infection and obliterative bronchiolitis. Transpl Int 2001; 14:234-9.
43. Moffatt SD, Demers P, Robbins RC, Doyle R, Wlenacker A, Henig N, et al. Lung transplantation: a decade of experience. J Heart Lung Transplant 2005; 24:145-51.
44. Brock MV, Borja MC, Ferber L, Orens JB, Anzcek RA, Krishnan J. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2001; 20:1282-90.
45. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320:1420-1.
46. Sevmis S, Emiroglu R, Karakayali F, Yagmurdur MC, Dalgic A, Moray G, et al. OKT3 treatment for steroidresistant acute rejection in kidney transplantation. Transplant Proc 2005; 37:3016-8.
47. Vallhonrat H, Williams WW, Cosimi AB, Tolkoff-Rubin N, Ginns LC, Wain JC, et al. In vivo generation of C4d, Bb, iC3b and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 1999; 67:253-8.
48. Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, et al. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 1990; 50:642-8.
49. Jensen PB, Birkeland SA, Rohrp N, Elbirk A, Jargensen KA. Development of anti-OKT3 antibodies after OKT3 treatment. Scand J Urol Nephrol 1996; 30:227-30.
50. Kirkman R, Shapiro M, Carpenter C, McKay D, Milford E, Ramos E, et al. A randomized prospective trial of anti-tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51:107-13.
51. Woodle ES, Thistlethwaite JR, Jolliffe LK, Zlvin RA, Collins A, Adair JR, et al. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 1992; 148:2756-63.
52. Woodle ES, Xu D, Zlvin RA, Auger J, Charette J, O'Laughlin R, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68:608-16.
53. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70:1707-12.
54. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival and patient survival after primary kidney transplantation. Transplantation 2003; 76:1289-93.
55. Meier-Kreische HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13:769-72.
56. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723-8.
57. Abbott KC, Hypolite I, Poropatich RK, Hshieh P, Cruess D, Hawkes CA, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001; 3:203-11.
58. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68-72.
59. Oh CS, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, Maki DG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988; 45:68-73.
60. Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11:112-9.
61. Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Henrich G, Schreier MH, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60:748-56.
62. Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999; 58:1029-42.
63. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplant Proc 1991; 23:1066-7.
64. van Gelder T, Zietse R, Mulder AH, Yzermans JN, Hesse CJ, Vaessen LM, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60:248-52.
65. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161-5.
66. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescotivz MD, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72:839-45.
67. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc 1998; 30:2155-8.
68. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67:110-5.
69. Hengster P, Pescovitz MD, Hyatt D, Mergreiter R. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999; 68:310-3.
70. Pescovitz MD, Knechtle S, Alexander SR, Colombani P, Nevins T, Nieforth K, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant 2008; 12:447-55.
71. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: A Review of its Use in the Management of Organ Transplantation. BioDrugs 2001; 15:745-73.
72. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002; 16:60-8.
73. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2:568-73.
74. Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7:560-70.
75. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-75.
76. Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20:1385-92.
77. Kock M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002; 73:1640-6.
78. Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Transplant Proc 2005; 37:1151-2.
79. Figueras J, Prieto M, Bernardo A, Rimola A, Suarez F, de Urbina JO, et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 2006; 19:641-8.
80. Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation 2008; 86:1689-94.
81. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11:61-7.
82. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342:613-9.
83. Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352:2705-13.
84. Ortiz V, Almenar L, Martinez-Dolz L, Zorio E, Chamorro C, Moro J. Induction therapy with daclizumab in heart transplantation-how many doses? Transplant Proc 2006; 38:2541-3.
85. Potter BJ, Giannetti N, Routy JP, Cecere R, Cantarovich M. CD25 saturation rate in heart transplant patients receiving two-dose daclizumab induction. Transplantation 2005; 79:857-8.
86. Mullen JC, Oreopoulos A, Lien DC, Bentley MJ, Modry DL, Stewart K, et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007; 26:504-10.
87. Lischke R, Simonek J, Davidva R, Schutzner J, Stolz AJ, Vojacek J, et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc 2007; 39:205-12.
88. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350:1193-8.
89. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67:276-84.
90. Mulloy LL, Wright F, Hall ML, Moore M. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant Proc 1999; 31:1210-3.
91. Sheashaa HA, Bakr MA, Ismail AM, Sobh MA, Ghoneim MA. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol 2003; 16:393-8.
92. Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72:1261-7.
93. Duzova A, Buyan N, Bakkaloglu M, Dalgic A, Soylemezoglu O, Besbas N, et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc 2003; 35:2878-80.
94. Offner G, Toenshoff B, Hocker B, Krauss M, Bulla M, Cochat P, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil and steroids. Transplantation 2008; 86:1241-8.
95. Matl I, Bachleda P, Lao M, Michalsky R, Navratil P, Treska V. Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine. Transpl Int 2003; 16:45-52.
96. Matl I, Bachleda P, Michalsky R, Navratil P, Lao M, Treska V, et al. Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine. Transplant Proc 2001; 33:3205-6.
97. Baquero A, Perez J, Rizik N, Lafontaine H, Carretero V, Suero F, et al. Basiliximab: a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation. Transplant Proc 2006; 38:909-10.
98. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776-85.
99. Emparan C, Laukotter M, Wolters H, Dame C, Heidenreich S, Senninger N. Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function. Transplant Proc 2003; 35:1326-7.
100. Tojimbara T, Sato S, Koyama I, Nanmoku K, Sekijima M, Tonsyo M, et al. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil. Transplant Proc 2005; 37:895-8.
101. Mariat C, Afiani A, Alamartine E, Thibaudin D, de Filippis JP, Berthoux F. A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients. Transplant Proc 2001; 33:3192-3.
102. Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Tranplant 2002; 2:48-56.
103. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8:132-42.
104. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8:123-31.
105. Marino IR, Doria C, Scott VL, Foglieni CS, Lauro A, Piazza T, et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Transplantation 2004; 78:886-91.
106. Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005; 11:1258-64.
107. + Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78:1488-95.
108. Llado L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14:1752-60.
109. Marubashi S, Dono K, Amano K, Hama N, Gotoh K, Takahashi H, et al. Steroid-free living-donor liver transplantation in adults. Transplantation 2005; 80:704-6.
110. Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24:1297-304.
111. Rosenberg PB, Vriesendorp AE, Drazner MH, Dries DL, Kaiser PA, Hynan LS, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24:1327-31.
112. Flaman F, Zieroth S, Rao V, Ross H, Delgado DH. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 2006; 25:1358-62.
113. Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D, et al. Basiliximab and rabbit antithymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007; 26:258-63.
114. Borro JM, De la Torre M, Miguelez C, Fernandez R, Gonzalez D, Lemos C, et al. Comparative study of basiliximab treatment in lung transplantation. Transplant Proc 2005; 37:3996-8.
115. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3:137-43.
116. Friend PJ, Waldmann H, Hale G, Cobbold S, Rebello P, Thiru S, et al. Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc 1991; 23:2253-4.
117. Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, et al. Campath IH allows lowdose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613-6.
118. Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005; 37:923-6.
119. Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006; 19:885-92.
120. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction - long-term results. Am J Transplant 2005; 5:2539-48.
121. Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, et al. Steroid-free tacrolimus monotherapy after pretransplantation RATG or Campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005; 37:4235-40.
122. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83:1509-12.
123. Munoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up. Transplant Proc 2008; 40:2230-3.
124. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 2008; 8:1480-5.
125. Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77:1209-14.
126. Reams BD, Musselwhite LW, Zaas DW, Steele MP, Garantziotis S, Eu PC, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 2007; 7:2802-8.